Neuropathy and Anti-GFAP Antibodies

NCT ID: NCT05742087

Last Updated: 2023-02-23

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 120 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-09-01
• Study Completion Date: 2023-05-01

Brief Summary

Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also expressed by immature and non-myelinating Schwann cells. Thus, these antibodies could also lead to damages of the peripheral nervous system (PNS). Moreover, such damages have already been reported on small studies, and there is a need for larger cohorts.

The investigators will use the cohort of patients with neurological syndromes and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Reference center for paraneoplastic neurological syndromes and autoimmune encephalitis" to determine the frequency of the PNS involvement in these patients.

Conditions

Neurological Diseases or Conditions; Neurological Diseases Associated to Anti GFAP Antibodies

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Patients presenting with neurological symptoms and anti-GFAP antibodies in the CSF.

This is a non-interventional study involving biological samples. Samples are already stored in biobank repositories and collected as part of "good clinical practice" in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the "iological Resource Center of the Hospices Civils de Lyon" (CRB-HCL) (including tissue, cells or biological fluids).

The group will be composed of patients included in the French cohort of patients with neurological syndromes and anti-GFAP antibodies in the CSF.

Clinical examination

Intervention Type: OTHER

The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.

electroneuromyography (ENMG)

Intervention Type: OTHER

Data from the ENMGs will be extracted from the cohort and analyzed.

Interventions

Clinical examination

The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.

Intervention Type: OTHER

electroneuromyography (ENMG)

Data from the ENMGs will be extracted from the cohort and analyzed.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• - Age > 18 years old
• Neurological symptoms
• Anti-GFAP antibodies identified in the CSF

Exclusion Criteria

• - Uncomplete data in the medical records of patients

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hospices Civils de Lyon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes

Lyon, , France

Countries

France

Other Identifiers

22-5018

Identifier Type: -

Identifier Source: org_study_id